<DOC>
	<DOCNO>NCT02091141</DOCNO>
	<brief_summary>This multicenter , non-randomized , open-label study design evaluate four treatment regimens patient advanced cancer available , beneficial treatment . Patients HER2 overexpression , amplification , -activating mutation treat Herceptin/Perjeta ; epidermal growth factor receptor ( EGFR ) , Tarceva ; BRAF-activating mutation , Zelboraf/Cotellic ; Hedehog pathway potentially clinically relevant mutation , Erivedge . Treatment continue disease progression unacceptable toxicity occur . Study expect last 5 year .</brief_summary>
	<brief_title>A Study Evaluating Herceptin/Perjeta , Tarceva , Zelboraf/Cotellic , Erivedge Treatment Targeted Against Certain Mutations Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Age &gt; /= 18 year Life expectancy &gt; /= 12 week Histologically document metastatic cancer ( solid tumor , include hematologic malignancy ) Molecular test result certified laboratory ( use tissue recent tumor biopsy metastatic setting ) show least one follow abnormality : HER2 overexpression , amplification , HER2activating mutation EGFRactivating mutation BRAFactivating mutation Hedgehog pathway potentially clinically relevant mutation ( activate mutation SMO lossoffunction mutation PTCH1 ) Patients received standard firstline therapy metastatic cancer ( except tumor firstline therapy exists ) trial target therapy consider best available treatment option . Eligible patient available therapy convey clinical benefit . No previous treatment specific assign study drug drug share target Progressive cancer time study entry Measurable evaluable disease RECIST v. 1.1 Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) score 0 , 1 , 2 Adequate hematologic , renal , liver function Use effective contraception define protocol Studydrug specific criterion : Trastuzumab plus Pertuzumab Patients solid tumor HER2 overexpression , amplification , HER2activating mutation Patients breast , gastric , gastroesophageal junction cancer must HER2activating mutation . Left ventricular ejection fraction ( LVEF ) &gt; 50 % low limit institutional normal range , whichever low Erlotinib Patients solid tumor harbor EGFRactivating mutation Vemurafenib BRAF mutation positivity determine next generation sequencing ( NGS ) real timepolymerase chain reaction ( RTPCR ) accept . Vismodegib Hedgehogactivating mutation positivity All nonhematological adverse event related prior chemotherapy , surgery , radiotherapy must resolve National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Grade &lt; /= 2 prior start therapy . Patients hematologic malignancy Concurrent administration anticancer therapy ( except male patient prostate cancer receive androgen blockade ) Bisphosphonates denosumab allow . Most recent anticancer therapy &lt; /= 28 day recover side effect , exclude alopecia Radiaiton therapy within ≤ 14 day Active untreated brain metastasis History carcinomatous meningitis Uncontrolled concurrent malignancy ( early stage allow require active therapy intervention ) Women breastfeed pregnant Any significant cardiovascular event within 6 month prior study entry . Pulmonary embolism within 30 day prior study entry History presence clinically significant ventricular atrial dysrhythmia &gt; Grade 2 ( National Cancer Institute Common Terminology Criteria Adverse Events version 4.0 [ NCI CTCAE v4.0 ] ) Any severe acute chronic medical psychiatric condition laboratory abnormality Eligible another actively accrue Roche/Genentechsponsored interventional clinical trial Studydrug specific criterion : Trastuzumab plus Pertuzumab Breast , gastric , gastroesophageal junction cancer identify HER2 amplification overexpression Previous treatment HER2targeted therapy Erlotinib Nonsmall cell lung cancer ( NSCLC ) pancreatic cancer identify exon 19 exon 21 mutation Cancers exon 20 mutation Previous treatment erlotinib EGFR inhibitor Vemurafenib plus Cobimetinib Malignant melanoma , papillary thyroid cancer , colorectal cancer , hematologic malignancy include multiple myeloma Left ventricular ejection fraction ( LVEF ) institutional low level normal ( LLN ) 50 % , whichever low History evidence retinal pathology ophthalmologic examination consider risk factor neurosensory retinal detachment , retinal vein occlusion ( RVO ) , neovascular macular degeneration Presence follow condition , risk factor RVO : Uncontrolled glaucoma intraocular pressure &gt; 21 mm Hg , Serum cholesterol &gt; /= Grade 2 , Hypertriglyceridemia &gt; /= Grade 2 , Hyperglycemia ( fast ) &gt; /= Grade 2 Prior concurrent malignancy know RAS mutation Previous treatment vemurafenib BRAF inhibitor ( prior sorafenib allow ) Previous treatment cobimetinib RAF inhibitor Prior treatment MEK inhibitor Corrected QT ( QTc ) interval ≥450 msec baseline history congenital long QT syndrome Vismodegib Basal cell carcinoma skin , medulloblastoma , smallcell lung cancer , hematologic malignancy Previous treatment vismodegib hedgehog pathway inhibitor Breast cancer patient take hormone replacement therapy hormonal birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>